Accepted Manuscript

Design and development of microemulsion systems of a new antineoplaston A10 analog for enhanced intravenous antitumor activity: *In vitro* characterization, molecular docking, ¹²⁵I-radiolabeling and *in vivo* biodistribution studies

Mohamed H. Aboumanei, Aly A. Abdelbary, Ismail T. Ibrahim, Mina I. Tadros, Mohamed T. El-Kolaly


PII: S0378-5173(18)30302-8

DOI: https://doi.org/10.1016/j.ijpharm.2018.05.010

Reference: IJP 17481

To appear in: International Journal of Pharmaceutics

Received Date: 31 January 2018 Revised Date: 30 April 2018 Accepted Date: 2 May 2018



Please cite this article as: M.H. Aboumanei, A.A. Abdelbary, I.T. Ibrahim, M.I. Tadros, M.T. El-Kolaly, Design and development of microemulsion systems of a new antineoplaston A10 analog for enhanced intravenous antitumor activity: *In vitro* characterization, molecular docking, ¹²⁵I-radiolabeling and *in vivo* biodistribution studies, *International Journal of Pharmaceutics* (2018), doi: https://doi.org/10.1016/j.ijpharm.2018.05.010

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

ACCEPTED MANUSCRIPT

Design and development of microemulsion systems of a new antineoplaston A10 analog for enhanced intravenous antitumor activity: *In vitro* characterization, molecular docking, ¹²⁵I-radiolabeling and *in vivo* biodistribution studies

Mohamed H. Aboumanei¹, Aly A. Abdelbary^{2,3*}, Ismail T. Ibrahim¹, Mina I. Tadros², Mohamed T. El-Kolaly¹

¹Labeled Compounds Department, Hot Lab Center, Egyptian Atomic Energy Authority, Cairo, 11371, Egypt

²Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Cairo University, Cairo, 11562, Egypt

³Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, October 6 University, Giza, 12585, Egypt

Abstract

A10, (3-phenylacetylamino-2,6-piperidinedione), is a natural peptide with broad antineoplastic activity. Recently, *in vitro* antitumor effect of a new A10 analog [3-(4-methoxybenzoylamino)-2,6-piperidinedione] (MPD) has been verified. However, poor aqueous solubility represents an obstacle towards intravenous formulation of MPD and impedes successful *in vivo* antitumor activity. To surmount such limitation, MPD microemulsion (MPDME) was developed. A 3¹2² full factorial design using Design-Expert[®] software was adopted to study the influence of different parameters and select the optimum formulation (MPDME1). Transmission electron microscopy (TEM) displayed spherical droplets of MPDME1. The cytotoxicity of MPDME1 in Michigan Cancer Foundation 7 (MCF-7) breast cancer cell line exceeded that of MPD solution (MPDS) and tamoxifen. Compatibility with

Download English Version:

https://daneshyari.com/en/article/8519810

Download Persian Version:

https://daneshyari.com/article/8519810

<u>Daneshyari.com</u>